Le Lézard
Classified in: Health
Subject: PDT

The new Lutronic LaseMD is changing the way practices think about skin rejuvenation.


BOSTON, Jan. 23, 2018 /PRNewswire/ -- Lutronic announced today the availability of LaseMD, a 1927nm Thulium laser. This latest innovation allows physicians to offer skin resurfacing to every patient, regardless of skin type or age.  Designed with the physician in mind, the novel features range from the award winning ergonomic design to the combined ease and speed of operation, which make the treatment a breeze to perform. "While I have been using the 1927 wavelength for years, the LaseMD is unique." Shared Dr. Robert Weiss, Director of Maryland Dermatology Laser Skin and Vein Institute, "The simplicity and ease of use combined with the complete control over degree of treatment from mild to aggressive, makes LaseMD the thulium laser of choice from now on."

LaseMD system

The broad range of treatment settings, from gentle to aggressive, ensure greater control over outcomes. Cleared for actinic keratosis, benign pigmented lesions and a variety of other conditions, this groundbreaking device is more than just pretty, it performs.  "The LaseMD fits wonderfully within my practice," stated Dr. Gilly Munavalli, Director of Dermatology Laser and Vein Specialists of North Carolina, "and strikes a good balance between downtime and results. My patients love their results and report they love the visible and textural changes. It truly is skin brightening."

Additionally, a line of specially formulated ampoules, masks and cream are available to enhance the LaseMD patient experience, which patients are raving about. The ampoules feature Vitamin C, Vitamin A, Resveratrol and Tranexamic Acid can be taken home by the patients to complement their in-office treatment. The ampoule and mask combined, allow physicians to provide their patients a completely luxurious 'LaseMD Experience'. The enhanced treatment is so well liked by patients that it has become a high demand treatment in clinics worldwide.

Featured at AAD in San Diego, physicians can stop by the Lutronic booth to learn more about this unique device, try it for themselves, receive free sample of the Ampoules and hear leading physicians speak about it in the booth.  There will also be an upcoming webinar on January 25th at 7 pm EST entitled "Resurfacing for Every Patient" and will feature renowned physicians, Robert Weiss, MD, FAAD, FACPh, Director of Maryland Dermatology Laser Skin and Vein Institute and Gilly Munavalli, MND, MHS, FACMS of Dermatology Laser and Vein of the Carolinas. 

"The release of LaseMD in the US is just the latest in many exciting things to come for Lutronic," stated Jeff Knight, President of Lutronic Global, "By moving our global headquarters to the USA, we are primed to improve our product offerings and further expand our global reach."  After celebrating its first 20 years, Lutronic is in a great position to take the aesthetic market by storm; a complete complement of workhorse products, combined with a vision that will lead the company into many more successful years.

About LaseMD
Dramatically different, LaseMD simply delivers glowing rejuvenated skin through gentle but effective non-ablative fractionated treatments with minimal downtime. LaseMD offers customized skin resurfacing for every patient. It works by creating micro-channels with minimal disruption to the stratum cornium while leaving bridges of untouched tissue for improved permeability, fast healing and reduced downtimes. From the award winning, ergonomic design to the patented intelligent features that improve tracking, speed and outcomes, LaseMD has been developed for the physician with the patient in mind.

About LUTRONIC
Lutronic, a leading innovator in advanced aesthetic and medical laser and related technology, was established in 1987 to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, Lutronic partners with key opinion leaders to advance science and ensure the efficacy of its systems.  All systems are versatile and offer multiple settings and treatment options for customized treatments, which optimize outcomes for a wide variety of conditions in the fields of aesthetics, spine surgery and ophthalmology. 

With a focus on physician needs and patient outcomes, Lutronic dedicates time and funding toward the development of devices that offer features and improvements not found in today's market. Devoting more than 20% of revenues to R&D, Lutronic holds more than 200 current and pending patents worldwide. With Global Headquarters located in the US, Lutronic also has a Center in Korea, offices in Germany, China and Japan and a world-wide network of distributors that is ever expanding. 

Lutronic Contact
Tracy Geisler-Evleshin
Global Marketing Communications Director
[email protected]
408-805-0096

 

LaseMD Glo treatment results.

SOURCE Lutronic


These press releases may also interest you

at 18:00
Bridge Biotherapeutics (KQ288330), a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr. Jessica M. Konen's Lab at Emory University School of Medicine....

at 17:58
More than 200 workers at American Medical Response (AMR) in Springfield and Greenfield have voted overwhelmingly to join Teamsters Local 404....

at 17:54
The American Association of Kidney Patients (AAKP), the largest and oldest independent kidney patient organization in the nation, is celebrating National Doctors Day by highlighting three top kidney medical experts and authors known for their...

at 17:20
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024. One individual was...

at 17:15
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...

at 17:05
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...



News published on and distributed by: